Hangil Park

US Patent:

8101723, Jan 24, 2012

Filed:

Nov 6, 2009

Appl. No.:

12/614282

Inventors:

Kyung Jin Kim - Cupertino CA, US
Wei-meng Zhao - Palo Alto CA, US
Hangil Park - San Francisco CA, US
Maximiliano Vasquez - Palo Alto CA, US

Assignee:

Galaxy Biotech, LLC - Cupertino CA

International Classification:

C12P 21/08
C07K 16/00
A61K 39/00
A61K 39/395

US Classification:

5303873, 5303881, 53038815, 53038822, 4241331, 4241411, 4241421

Abstract:

The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.

US Patent:

8101725, Jan 24, 2012

Filed:

May 28, 2009

Appl. No.:

12/474198

Inventors:

Kyung Jin Kim - Cupertino CA, US
Lihong Wang - Palo Alto CA, US
Hangil Park - San Francisco CA, US
Maximiliano Vasquez - Palo Alto CA, US

Assignee:

Galaxy Biotech, LLC - Cupertino CA

International Classification:

C07K 16/22
A61K 39/395

US Classification:

5303881, 53038824, 4241411, 4241421, 4241451

Abstract:

The present invention is directed toward a neutralizing monoclonal antibody to basic fibroblast growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.

US Patent:

8603987, Dec 10, 2013

Filed:

Oct 28, 2011

Appl. No.:

13/284838

Inventors:

Kyung Jin Kim - Cupertino CA, US
Wei-meng Zhao - Palo Alto CA, US
Hangil Park - San Francisco CA, US
Maximiliano Vasquez - Palo Alto CA, US

Assignee:

Galaxy Biotech, LLC - Cupertino CA

International Classification:

A61K 38/00
C12P 21/08
C07K 16/00
A61K 39/395

US Classification:

514 193, 5303873, 5303881, 53038815, 53038822

Abstract:

The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.

US Patent:

8628778, Jan 14, 2014

Filed:

Sep 29, 2009

Appl. No.:

12/569463

Inventors:

Kyung Jin Kim - Cupertino CA, US
Hangil Park - San Francisco CA, US
Lihong Wang - Palo Alto CA, US
Maximiliano Vasquez - Palo Alto CA, US

Assignee:

Galaxy Biotech, LLC - Sunnyvale CA

International Classification:

A61K 39/395

US Classification:

4241451, 4241411, 4241361, 4241331, 4241301

Abstract:

The present invention is directed toward a humanized neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.

US Patent:

20080019974, Jan 24, 2008

Filed:

Mar 29, 2007

Appl. No.:

11/731774

Inventors:

Kyung Kim - Cupertino CA, US
Hangil Park - San Francisco CA, US
Lihong Wang - Palo Alto CA, US
Maximiliano Vasquez - Palo Alto CA, US

Assignee:

Galaxy Biotech, LLC - Cupertino CA

International Classification:

A61K 39/395
A61P 35/00
C07K 16/22
C12P 21/08

US Classification:

424145100, 435336000, 530388150

Abstract:

The present invention is directed toward a humanized neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.

US Patent:

20130209482, Aug 15, 2013

Filed:

Dec 15, 2011

Appl. No.:

13/327624

Inventors:

Kyung Jin Kim - Cupertino CA, US
Lihong Wang - Palo Alto CA, US
Hangil Park - San Francisco CA, US
Maximiliano Vasquez - Palo Alto CA, US

Assignee:

Galaxy Biotech, LLC - Cupertino CA

International Classification:

C07K 16/28

US Classification:

4241451, 53038824, 5303873, 53038815

Abstract:

The present invention is directed toward a neutralizing monoclonal antibody to basic fibroblast growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.

US Patent:

20210238297, Aug 5, 2021

Filed:

Feb 2, 2021

Appl. No.:

17/165818

Inventors:

- CUPERTINO CA, US
Hangil Park - San Francisco CA, US
Lihong Wang - Hayward CA, US
Yi Ding - Milpitas CA, US
April Zhang - San Jose CA, US
Maximiliano Vasquez - Palo Alto CA, US

Assignee:

GALAXY BIOTECH, LLC - CUPERTINO CA

International Classification:

C07K 16/28
A61P 35/00

Abstract:

The present invention is directed toward monoclonal antibodies that bind to death receptor 4 and/or death receptor 5, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.

US Patent:

20210079096, Mar 18, 2021

Filed:

Aug 28, 2020

Appl. No.:

17/006670

Inventors:

- South San Francisco CA, US
Alessandro PALUMBO - South San Francisco CA, US
Kathy MILLER - South San Francisco CA, US
Hangil PARK - South San Francisco CA, US
Nerissa MENDOZA - South San Francisco CA, US
Majid GHODDUSI - South San Francisco CA, US

International Classification:

C07K 16/28
G01N 33/574

Abstract:

The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4. The anti-B7-H4 antibodies or antigen-binding fragments thereof are useful, for example in detecting B7-H4. Immunohistochemistry (IHC) can be used to detect B7-H4 The present disclosure also provides methods for treating cancer wherein increased B7-H4 has been detected, by administering a therapeutic anti-B7-H4 antibody or antigen-binding fragment thereof.